Haematology Flashcards
Lab criteria APLS
- Lupus anticoagulant
> Prolonged APTT that fails to correct with mixing with prolonged reptiliase time - Anticardiolipin antibody >99th percentile
- Anti-B2 glycoprotein -1 antibody >99th percentile
Must be present on 2 occasions 12 weeks apart
Clinical criteria APLS
One or more arterial, venous thrombosis
One of more unexplained fetal deaths over 10 weeks gestation
One or more Premature birth before 34 weeks
Three or more unexplained miscarriages before 10 weeks
Anticoagulation for Antiphospholipid Ab and 1 foetal loss at ten weeks
Low dose aspirin/prophylactic LMWH during pregnancy
Post partum prophylaxis
Antiphospholipid Ab and no thrombosis or pregnancy complications
Post partum prophylaxis for 6/52
Pregnancy anticoagulation for Lab criteria + Clinical pregnancy criteria of 3 or more pregnancy losses
Antepartum prophylactic clexane + aspirin
Dabigatran benefit over warfarin in AF
Less ICH
Increased GI bleeding
Small increase in myocardial infarction
Dabigatran reversal agent
Idarucizumab 5g
Factors in Prothrombin X
IX, X, II
Tranexamic acid mechanism
inhibits the activation of plasminogen via binding at several distinct sites, the latter of which is a lysin residue involved in its binding to fibrin
FXa inhibitor antidote
Andexanet alpha
Antedote for apixaban, rivaroxaban
Factor 13
Coagulation factor XIII (FXIII) is converted by thrombin and Ca(2+) into an active transglutaminase (FXIIIa) in the final phase of coagulation cascade. Its main function is the mechanical stabilization of fibrin clot and its protection from fibrinolysis by cross-linking of fibrin chains and α(2)-plasmin inhibitor to fibrin
Haemophilia C
Factor 11 deficiency
FVIII/IX deficiency severity
<1 severe- spontaneous
1-5% mod - surgery/minor trauma
>5 mild - major trauma
Cryoprecipitate contents
Factor VIII, fibrinogen, Factor XIII, vWF and fibronectin from the FFP
Only used to replace fibrinogen nowdays
Biostate contents
FVIII + vWF
Factor IX replacements
MonoFIX - plasma derived
Benefix - recombinant
Desmopressin/ DDAVP (ADH)
Increases in FVIII and vWF
Treatment in mild T1 vWFD
Treatment of acquired inhibitors
Novoseven
Bernard-Soulier syndrome
Abnormality of platelet glycoprotein 1b-IX-V, a receptor for vWF
Glanzmann thrombasthenia
Defect in glycoprotein IIb/IIIa complex
Peak timing of thrombocytopaenia in gestational thrombocytopaenia
2 and 3rd trimester
Mechanism and treatment of idiopathic TTP
Autoimmune ADAMTS13 deficiency
Treated with PLEX
Treatent of HITTS
Fondaparinux
Bivalirudin - renal impaired
action of hepcidin in Anaemia CD
Increased hepcidin
Blocks ferroportin
Unable to absorb iron
HbH
Beta tetramers
Hb Barts
Gamma tetramers
HbA2
Alpha x2 Delta x 2
Intravascular haemolytic
Urine haemosiderin
Emicizumab
Treatment for haemophilia A
Bridges factor 9 and 10 in similar mechanism to factor 8
Smudge/smear cells
CLL
Lab/imaging reasons to treat MM
60% plasma cells
Serum free light chains >100
reater than one focal lesion on MRI
APML mutation
t(15;17)
APML RX
ATRA
Arsenic